Enfuvirtide: antiretroviral class 4, drug 1.
With the licensing of enfuvirtide, physicians prescribing antiretroviral medications now have available the first of a new class of drugs, the fusion inhibitors. In this article, enfuvirtide is discussed with particular emphasis on the clinical trials that led to the drug's licensing. The possible placement of enfuvirtide in the sequence of treatment is also discussed.
Chelsea and Westminster Hospital, London, UK. david.asboe@chelwest.nhs.uk
David
D
Asboe
D004334:Drug Administration Schedule; D024882:Drug Resistance, Viral; D000077560:Enfuvirtide; D015700:HIV Envelope Protein gp41 / Q000187:drug effects / Q000494:pharmacology*; D023581:HIV Fusion Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D010446:Peptide Fragments / Q000494:pharmacology*; D016032:Randomized Controlled Trials as Topic; D019713:Receptors, CCR5 / Q000187:drug effects; D019718:Receptors, CXCR4 / Q000187:drug effects; D014760:Viral Fusion Proteins / Q000037:antagonists & inhibitors
D015700:HIV Envelope Protein gp41; D023581:HIV Fusion Inhibitors; D010446:Peptide Fragments; D019713:Receptors, CCR5; D019718:Receptors, CXCR4; D014760:Viral Fusion Proteins; D000077560:Enfuvirtide